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A B S T R A C T   
Objective: Irritability is a highly burdensome complaint, commonly, but not universally, linked with depressive 
symptoms. While increased variability in estradiol has been associated with depressive symptoms during peri-
menopause, more insight is needed into reproductive hormone dynamics and other factors that predispose 
perimenopausal women to irritable mood. 
Methods: Among 50 mildly depressed perimenopausal women (mean (SD) age 48.4 (3.9) years), severity of ir-
ritability symptoms (on Symptom Questionnaire Hostility subscale, range 0–23) was assessed weekly for eight 
weeks, concurrent with potential predictors. Associations between these were examined using generalized 
estimating equating models. 
Results: Most women (82.0%) reported having moderate to severe irritability at least once. However, the severity 
of irritability was highly variable from week-to-week (between-subject mean coefficient of variation [CV] 72.9% 
and within-subject mean CV 63.7%). In multivariate analyses, less variable serum estradiol levels (standardized β 
within-person CV − 0.23 95%CI [− 0.32, − 0.14], p < 0.001), greater depression severity (0.45 [0.35, 0.56], 
p < 0.001), younger age (− 0.23, [− 0.28, − 0.09], p < 0.001), and more frequent vasomotor symptoms (0.14 
[0.05, 0.23], p = 0.002) were associated with more irritability. Depression severity explained the largest portion 
of the variance in irritability, but still not more than 20.3%. Neither crude values, weekly change in, or vari-
ability of progesterone or FSH levels were associated with irritability. 
Conclusions: Irritability was highly prevalent among mildly depressed perimenopausal women. In contrast to 
depressive symptoms, decreased rather than increased variability in estradiol levels was associated with more 
irritability. This highlights that irritable mood can be disentangled from depressive symptoms in perimenopausal 
women and might be linked with different estradiol dynamics.   
1. Introduction 
Irritability, defined as a low threshold for experiencing frustration or 
anger, is prevalent during the perimenopause (Freeman et al., 2008; 
Bromberger et al., 2003; Mauas et al., 2014). Perimenopausal women 
complain 41.2% more often about irritability compared to premeno-
pausal women (Bromberger et al., 2003). Though often coincidental 
with depression (Fava et al., 2010), irritability is a distinct dysphoric 
mood state (Toohey and DiGiuseppe, 2017). Its presence decreases 
quality of life, (Berk et al., 2017) and is associated with greater severity 
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of depressive symptoms (Perlis et al., 2009). In addition to this personal 
burden, irritability, more than depressive symptomatology, may pro-
voke excessive frustration among others (Reinares et al., 2006). Unfor-
tunately, identification of underlying processes that predispose 
perimenopausal women to irritability, has garnered little attention. 
Patterns of reproductive hormones are of particular interest as the 
perimenopause is characterized by more marked fluctuations of serum 
estradiol, alternating with periods of sustained lower and unchanging 
levels of estradiol, resulting in less predictable ovulation (Hale et al., 
2014; Butler and Santoro, 2011). Moreover, previous research has 
shown that greater variability in estradiol levels (Freeman et al., 2006; 
Gordon et al., 2016a, 2016b; Joffe et al., 2020), and absence of ovulation 
as measured with progesterone (Joffe et al., 2020), is associated with 
more depressive symptomatology during the perimenopause. 
Three large studies have examined risk factors for irritability, 
defined using a single question, in midlife women transitioning from 
pre- to post-menopause (Freeman et al., 2008; Bromberger et al., 2003, 
2001). Only one of these, the Penn Ovarian Aging Study, investigated 
reproductive hormone patterns (Freeman et al., 2008). This study 
showed that mean levels of estradiol or follicle stimulation hormone 
(FSH) obtained every nine to twelve months over nine years were not 
associated with concurrent moderate to severe irritability (Freeman 
et al., 2008). However, measuring hormone levels approximately 
annually does not capture the dynamics of the perimenopause, and other 
hormones of interest, such as progesterone, were not examined. The two 
other studies that investigated menopause-related risk factors for irri-
tability in women across the menopausal transition originated from the 
Study of Women’s Health Across the Nation (SWAN) cohort. Here it was 
shown that more frequent vasomotor symptoms (VMS) and difficulty 
sleeping were associated with higher odds of severe irritability (Brom-
berger et al., 2003, 2001). 
Together, insight in menopause-related factors and specific hormone 
dynamics that predispose perimenopausal women to irritability is 
limited, but much needed. In the current study, we sought to determine 
which characteristics influence vulnerability to irritability as part of a 
dysphoric mood presentation during the perimenopause. To accomplish 
this, we conducted an eight-week observational study in perimeno-
pausal women with untreated depressive symptoms, whereby weekly 
assessments of reproductive hormones and other predictors were ob-
tained concurrent with assessment of irritability and depressive symp-
toms using well validated questionnaires. 
2. Methods 
2.1. Participants 
Data were derived from 50 perimenopausal women who were 
enrolled in an eight-week observational study. Perimenopausal status 
was defined using the Stages of Reproductive Aging Workshop (STRAW) 
criteria (Harlow et al., 2012). Subjects were included based on 
mild-to-moderate depressive symptoms defined as a score 10–25 on the 
Montgomery-Åsberg Depression Rating Scale (MADRS) (Montgomery 
and Asberg, 1979), and/or moderate irritability, defined as a score > 7.7 
on the Hostility scale of the Symptom Questionnaire (SQ) (Kellner, 
1987) to ensure that the sample represented the rich variety of mood 
symptoms that manifest during the perimenopause. Details of exclusion 
criteria are described in our previous work reporting the association of 
estradiol and progesterone variability with depressive symptoms 
severity (Joffe et al., 2020). All participants provided written informed 
consent for study procedures, which were approved by the Partners 
HealthCare Institutional Review Board and conducted at Massachusetts 
General Hospital and Brigham and Women’s Hospital. The dataset is 
comprised of 420 visits collected in 50 women in whom information on 
irritability occurring during the past week was available. 
Every week, women rated their level of irritability for the preceding 
seven days. Irritability was measured using the 23-item Hostility scale of 
the SQ (Kellner, 1987). Items were rated as yes or no, and a total score 
was calculated by summing up the individual item scores (range 0–23). 
A higher score indicates more irritability, and a score > 7.7 is indicative 
of at least moderate irritability (Kellner, 1987). The SQ has been vali-
dated and found to be highly sensitive in detecting irritability in pop-
ulations characterized by subclinical affective symptoms (Kellner, 1987; 
Benasi et al., 2020). Internal consistency was good in previous studies 
(Kellner, 1987; Grussu and Quatraro, 2013) and at our baseline assess-
ment (Cronbach’s alpha = 0.87). To provide insight into the variability 
of irritability within and between women, both within-person coeffi-
cient of variation (CV) ([personal SD irritability scoresvisit 1–9 / personal 
mean irritability scoresvisit 1–9]*100%) and between-person CV ([pop-
ulation SD irritability scoresvisit 1–9 / population mean irritability 
scoresvisit 1–9]*100%) were calculated. However, absolute irritability 
scores were used for the prediction model as the dependent variable, as 
described below. 
2.2. Hormonal predictors 
Serum levels of estradiol were measured weekly by liquid 
chromatography-mass spectrometry (LC-MS) (Mayo Clinic, Rochester, 
NY), with 10 pg/ml as the lower limit of detection and an inter-assay 
coefficient of variation of 8.6%. Participants with values below the 
detection limit (14 participants with 83 datapoints [19.7% of all data 
points]) were imputed with the value of 9 pg/ml. As a sensitivity ana-
lyses, measures were imputed with a different method. To this, we 
replaced the left-censored data (observations that are not quantified, but 
are known to be less than the detection limit) by a random draw from a 
distribution computed between zero and the lower limit of detection, 
imputing it using a log-transformation of the distribution (range of 
imputation from minus infinity to log10 pg/ml) (Helsel, 2011). Serum 
progesterone was measured by chemiluminescence immunoassays 
(Abbott Architect ci8200 and Beckman Coulter, Fullerton, CA). The 
lower level of detection of the assays was 0.10 ng/ml and 0.08 ng/ml, 
respectively. Serum follicle stimulation hormone (FSH) was measured 
by a chemiluminescence immunoassay (Ab bott Architect ci8200) that 
had a lower level of detection of 0.05 IU/l. The inter-assay CVs of the 
progesterone and FSH assays were ≤ 10%. From these values, we 
investigated three different hormonal predictors. The first contained the 
crude hormone levels. The second comprised a measure of variability of 
estradiol, progesterone and FSH within an individual woman. This 
within-person CV was calculated by dividing the within-subject stan-
dard deviation [SD] of hormone levelvisit 1–9 by the within-subject mean 
hormone levelvisit 1–9 multiplied by 100%. The third comprised a value 
of weekly changes in hormone levels which was calculated by sub-
tracting the value of hormone levelvisit x-1 from the value of hormone 
levelvisit x. This way, we tested whether the magnitude of change in 
hormone levels over the preceding week was associated with irritability 
levels during that same week. 
2.3. Other predictors 
At baseline, age, race, education, measured body mass index (BMI), 
recent stressful events, and lifetime history of Major Depressive Disorder 
(MDD) were collected. Race was collected as "Caucasian" (n = 30, 
60.0%), "Black" (n = 18, 36.0%), "Native American" (n = 1, 2.0%), and 
"Asian" (n = 1, 2.0%). For model simplicity however, race was dichot-
omized into Caucasian versus non-Caucasian. Whether participants ob-
tained a college degree was used to define education level. Lifetime 
MDD history was assessed by psychiatrists using an unstructured clinical 
interview. Number of recent stressful life events were self-reported using 
Life Experience Survey (LES) (Sarason et al., 1978). Severity of 
depressive symptoms was assessed weekly using the 10-item 
clinician-rated MADRS (ranges from 0 to 60, higher scores indicating 
higher severity). A score of 7–19 and 20–34 is commonly used to indi-
cate mild and moderate depression, respectively (McDowell, 2006). 
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Subjective daily VMS were assessed consistent with our previous 
approach, averaging number of VMS for the preceding week based on 
daily diary reporting (Joffe et al., 2020). Bi-weekly, participants 
completed the 7-item self-rated Insomnia Severity Index (ISI) ques-
tionnaire to measure the severity of insomnia over the last two weeks 
(Bastien et al., 2001). As scores reflected the severity of insomnia of the 
past two weeks, scores were used during two adjacent assessments to 
match the frequency of the weekly assessed predictors and outcome. 
2.4. Statistical analyses 
Sample characteristics were presented with means ± standard devi-
ation (SD), median with Interquartile Range (IQR), or by frequencies 
with percentages, dependent on the type and distribution of the vari-
able. As the data involved multiple within-person observations, we used 
generalized estimating equation (GEE) models with robust standard 
errors to determine the association of potential predictors with irrita-
bility, accounting for within-woman correlation (Herring, 2013). GEE 
models with different covariance structures were fitted using restricted 
maximum likelihood estimation, with “unstructured” chosen based on 
the Quasi-Akaiki Information Criterion. All GEE models were adjusted 
for the time between visits, and both independent (if not dichotomous) 
and dependent variables were standardized by subtracting the sample 
mean of the variable and dividing the result by the variable’s sample SD 
(z-scoring) to ease comparability of the strengths of the associations. 
First, we examined which variables predicted irritability. After uni-
variate models were determined, multivariate models were examined by 
adjusting for predictors that achieved statistical significance in univar-
iate analyses. For all these analyses, missing datapoints on estradiol 
(n = 2, 0.5%), FSH (n = 1, 0.2%), progesterone (n = 5, 1.2%), severity of 
depressive symptoms (n = 1, 0.2%), VMS (n = 61, 14.5%), or severity of 
insomnia (n = 56, 13.3%) were not imputed. Hence, these missings 
reduced the amount of available datapoints for some of the univariate 
models, and the multivariate model. Finally, the explained variance of 
irritability by variables that were significant in the multivariate analyses 
was determined by calculating the R2 of each of the variables (stan-
dardized β variable2*100%). 
Two post-hoc analyses were conducted. We first explored whether 
within-person mean estradiol might confound the association between 
variability of estradiol and irritability because the within-person CV is 
affected substantially by the mean value for each participant. To account 
for this possibility, we added within personal-mean estradiol to the 
multivariate model. In a separate analysis, we explored to what extent 
the direction of the association between the weekly changes in estradiol 
and irritability varied between women, consistent with a recent study 
(Gordon et al., 2020). We calculated for each woman the association of 
both crude and absolute values of weekly changes in estradiol with ir-
ritability and examined whether the association for each women was 
best described by absolute changes (increase and decrease in estradiol) 
or crude changes (increase or decrease, depending on the direction of 
the β) based on which β was largest in magnitude for a given woman. 
Statistics were conducted using RStudio (R version 3.6.0; R Foun-
dation for Statistical Computing, Vienna, Austria, 2016. URL: https:// 
www.R-project.org/), with main packages ‘gee’ (version 4.13–19), 
‘gmodels’ (version 2.18.1), and ‘ggplot2’ (version 3.2.1) packages. As 
multiple tests were performed, we calculated an adjusted False Discov-
ery Rate [FDR] P cut-off value to avoid the inflation of false-positive 
findings. A P-value of < 0.017 was considered statistically significant. 
3. Results 
3.1. Sample characteristics 
The characteristics of 50 perimenopausal women in the study are 
shown in Table 1. Subjects had a mean (SD) age of 48.4 (3.9) years and 
were on average slightly overweight (mean BMI [SD], 27.6 [6.6]). Most 
women (82.0%) reported having moderate to severe irritability at least 
once during follow-up. On average, irritability severity was within the 
subclinical range (median irritability score 5.5, IQR 3–9), but it differed 
substantially week-to-week, both between and within individual 
women. On average, the values of between-person variability over the 
eight-week study period (mean CV 72.9%) were greater than the within- 
person variability over the same timespan (mean CV 63.7%). Although 
one quarter (28.0%) of women had a history of MDD, the entire sample 
was only mildly depressed during the 8-week study (mean MADRS score 
10.8 [6.5]). 
3.2. Univariate analyses 
Results of univariate and multivariate analyses are shown in Table 2 
and Fig. 1. In univariate analyses, less variability in estradiol and higher 
depression severity were each associated with more irritability (stan-
dardized β for within-person CV estradiol − 0.12 with 95% Confidence 
Interval [CI] [− 0.20, − 0.03], p < 0.007, and for depression severity 
0.40 [0.311, 0.49], p < 0.001). More frequent VMS, younger age, and 
higher BMI each significantly predicted more irritability (standardized β 
[95%CI] 0.12 [0.02, 0.21], p = 0.015, − 0.12 [− 0.21, − 0.04], p = 0.005, 
and 0.24 [0.15, 0.34], p < 0.001, respectively). Neither absolute values, 
nor weekly changes in levels of estradiol, progesterone and FSH were 
predictive of irritability. Variability in progesterone and FSH were also 
not associated with irritability. 
Table 1 
Characteristics of 50 perimenopausal women.   
Perimenopausal 
women (n = 50)  
Mean / 
No. 
SD / % 
Age, mean (SD), y 48.4  3.9 
Race, no. Caucasian (%) 27  54.0 
Education, no. college degree (%) 22  44.0 
BMI (kg/m2), mean (SD) 27.2  6.6 
Lifetime history of MDD, no. (%) 14  28.0 
Depression severity (MADRS), mean (SD) 10.8  6.5 
VMS frequency, mean (SD) 2.6  3.1 
Insomnia severity (ISI), mean (SD) 10.6  5.1 
Serum reproductive hormone levels    
Estradiol, mean (SD), pg/ml 86.6  101.0 
Progesterone, mean (SD), ng/ml 2.0  4.2 
FSH, mean (SD), IU/L 34.5  36.6 
One-week change estradiol, mean (SD), pg/mla 0.1  103 
One-week change progesterone, mean (SD), ng/mla 0.1  5.5 
One-week change FSH, mean (SD), IU/La -0.2  12.2 
Variability estradiol, mean (SD)b 76.6  41.4 
Variability progesterone, mean (SD)b 107.0  69.9 
Variability FSH, mean (SD)b 49.1  25.0 
Irritability severity (Hostility scale SQ), mean (SD) 6.4  4.8 
Visits with at least moderate irritability (Hostility scale 
SQ >7.7), no (%) 
143  44.6 
Abbreviations: BMI, body mass index (calculated as weight in kilograms / by 
height in meters squared); FSH, follicle stimulating hormone; ISI, Insomnia 
Severity Index; MADRS, Montgomery-Åsberg Depression Rating Scale; SQ, 
Symptom Questionnaire; VMS, Vasomotor symptoms 
To convert estradiol pg/ml to pmol/l multiply by 3.67. To convert progesterone 
ng/ml to nmol/l multiply by 3.18. 
Age, Caucasian race, college graduate, BMI, history of MDD were determined at 
study entry. All other variables were assessed at every visit. 
a Differences in hormone levels between two successive visits (hormone lev-
elvisit x – hormone levelvisit x-1). 
b Within-person coefficient of variation ([within-subject standard deviation 
[SD] of hormone levelvisit 1–9 / within-subject mean hormone levelvisit 1–9]* 
100%). 
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3.3. Multivariate analyses 
In multivariate analyses, lower estradiol variability, worse depres-
sion severity, younger age, and more frequent VMS remained indepen-
dently associated with more irritability (standardized β [95%CI] − 0.23 
[− 0.32, − 0.14], p < 0.001, 0.45 [0.35, 0.56], p < 0.001, − 0.23 [− 0.32, 
− 0.14], p < 0.001, 0.14 [0.05, 0.23], p = 0.002, respectively). See also 
Table 2 and Fig. 1. Depression severity explained the largest proportion 
of the variance in irritability (20.3%), followed by age and estradiol 
variability (both 5.3%), and VMS frequency (2.0%). 
3.4. Sensitivity analyses 
A different imputation approach for estradiol levels below the 
detection limit did not change the findings meaningfully (data not 
shown). 
3.5. Post hoc analyses 
We explored whether the within-person mean estradiol might 
confound the association between variability of estradiol and irritabil-
ity. As shown in Fig. 2, there was a positive association between the 
mean and SD in estradiol levels for each participant. However, addition 
of mean estradiol to the multivariate model did not change the effect size 
of estradiol variability on irritability symptoms (change in β within- 
person CV estradiol = 0.0%). Variability in estradiol still significantly 
predicted irritability (standardized β [95%CI] − 0.23 [− 0.31, − 0.14], 
p < 0.001), but mean estradiol levels did not (− 0.08 [− 0.15, − 0.001], 
p = 0.05). 
As a second post-hoc analysis, we explored whether inter-individual 
differences in the direction of the associations between the weekly 
changes in estradiol and irritability might explain why the overall 
variability variable of estradiol was a predictor of irritability, but the 
weekly change variable was not (Gordon et al., 2020). The 
within-woman association of both crude and absolute values of weekly 
changes in estradiol with irritability varied greatly between women in 
strength and direction (range β for crude values of weekly changes: 
− 26.50 to 5.09; for absolute values of weekly changes: − 3.10 to 4.00). 
Analysis of the largest association in magnitude for each woman showed 
that some were sensitive to increases of estradiol (8.5%), some to de-
creases of estradiol (8.5%), and some to either increases or decreases 
(6.4%). However, for the majority (76.6%) of women, these associations 
were not significant. 
4. Discussion 
Irritability was highly prevalent in this cohort of mildly depressed 
perimenopausal women with weekly assessments over eight weeks. 
Women who had less variable serum estradiol levels, more frequent 
VMS, or who were younger, reported more irritability, associations that 
were independent of depression severity. Our results emphasize that 
irritability is an important symptom domain in mild depression during 
the perimenopause which can be disentangled from depressive symp-
toms and have hormonal risk factors that do not match those of 
depressive symptoms. 
The finding that less variable estradiol levels, in contrast to crude 
levels, were predictive of more irritability, underlines the importance of 
measuring hormone serially in order to capture their dynamics, rather 
than obtain a single hormone level value. Importantly, the association 
was not driven by the propensity of low variability of estradiol to be 
accompanied by low mean levels of estradiol. Previous studies in peri-
menopausal women examining variability in estradiol in relation to the 
specific mood symptoms of irritability are lacking. We and others have 
shown that greater weekly estradiol variability is associated with more 
depressive symptoms (Gordon et al., 2016a, 2016b; Joffe et al., 2020). 
Hence, our findings might be extrapolated to suggest that, while sup-
pression of estradiol variability might improve depressed mood, but not 
ameliorate irritability. This interpretation is supported by findings from 
two randomized controlled trials in 178 premenopausal and 725 early 
postmenopausal women, showing that estrogen supplementation im-
proves depressive symptoms but worsens or does not have change irri-
tability symptoms (Lundin et al. 2017; Gleason et al., 2015; Santoro 
et al., 2017). However, our findings are not consistent with those of a 
smaller trial (n = 16 for intervention and n = 18 for placebo) of peri-
menopausal depressed women showing that estradiol treatment im-
proves both irritability and depressive symptoms more than placebo 
(Schmidt et al., 2000). Taken together, these findings suggest that 
Table 2 
Associations of potential predictors with severity of irritability symptoms in 50 
perimenopausal women with mild-to-moderate depressive symptoms.   
Irritability (Hostility scale SQ) 
Univariatea Multivariateb 
β 95% CI p β 95% CI p 
Sex hormones       
Estradiol -0.03 -0.11, 
0.06 
.58    
Progesterone -0.04 -0.14, 
0.05 
.37    
FSH 0.02 -0.14, 
0.09 












.94    
Variability FSHd -0.07 -0.16, 
0.02 















.42    
Age -0.12 -0.21, 
-0.04 
.005 -0.23 -0.32, 
-0.14 
< .001 
Caucasian race -0.04 -0.24, 
0.15 
.64    
Education -0.13 -0.32, 
0.07 





.19    
BMI 0.24 0.15, 
0.34 
< .001 0.12 0.02, 
0.21 
.017 
VMS frequency 0.12 0.02, 
0.21 
.015 0.14 0.05, 
0.23 
.002 
Insomnia severity 0.12 0.02, 
0.22 





< .001 0.45 0.35, 
0.56 
< .001 




0.70    
Abbreviations: BMI, body mass index (calculated as weight in kilograms / by 
height in meters squared); FSH, follicle stimulating hormone; SQ, Symptom 
Questionnaire; VMS, Vasomotor symptoms 
Estimates are standardized B-coefficients determined by generalized estimating 
equation analyses. 
a Adjusted for days between visits. 
b Adjusted for a and for predictors that achieved statistical significance in 
univariate analyses 
c Crude differences in hormone levels between two successive visits (hormone 
levelvisit x – hormone levelvisit x-1) 
d Within-person coefficient of variation ([within-subject standard deviation 
[SD] of hormone levelvisit 1–9 / within-subject mean hormone levelvisit 1–9]* 
100%) 
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Fig. 1. Predictors of irritability that achieved the significance threshold in the multivariate analyses in 50 perimenopausal women with mild-to-moderate depressive 
symptoms. Abbreviations: cv, coefficient of variation; MADRS, Montgomery Åsberg Depression Rating Scale; VMS, vasomotor symptoms. Significant predictors of 
irritability in perimenopausal women in multivariate analysis. Regression lines were fitted. Note that this is a presentation of the mean raw data per participant and 
that this does not fully correspond with the way the data was analyzed (multilevel). 
Fig. 2. Variability of serum estradiol levels over 8 weeks (a) and the association of mean serum estradiol levels with SD estradiol (b), showing that women with more 
variability in estradiol also have on average higher mean estradiol levels over the visits compared to women with less estradiol variability. Fig. A shows lines that 
represent serum estradiol levels within individual women selected from the upper and lower quintiles of the within-person coefficient of variation of estradiol 
(n = 20). Fig. B shows dots for the intersection of mean estradiol and the SD of estradiol for each of the participants (n = 50). The dots are labeled with the cor-
responding within-person coefficient of variation (in %) for estradiol. 
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different hormonal mechanisms may underlie irritability and depressive 
symptoms as mood symptoms that can be disentangled during the 
perimenopause, although further studies are needed to examine the 
specific mechanisms involved. 
There are many potential ways through which estradiol may be 
involved in affect regulation and dysregulation. Evidence supporting 
this statement is reviewed in detail elsewhere (Rubinow and Girdler, 
2011), but include the following: (a) Estradiol can regulate gene tran-
scription by intracytoplasmic receptor binding. These estrogen receptors 
are predominantly located in regions of the limbic system, such as the 
amygdala (Barth et al., 2015). This system is important for emotion 
regulation and implicated in affective disorders such as depression, but 
also premenstrual dysphoric disorder (PMDD) in which irritability is a 
cardinal symptom (Wharton et al., 2012) (b). Estradiol can alter release 
of all classical neurotransmitters, such as serotonin (Barth et al., 2015). 
The role of serotonin in the pathophysiology of affective disorders is 
supported by numerous findings using indirect measures of central se-
rotonin and its transmission (Wharton et al., 2012) (c). E2 modulates 
systems implicated in the pathophysiology of affective disorders such as 
the hypothalamic-pituitary-adrenal (HPA) axis and the immune system 
(Pitsillou et al., 2019). However, the exact mechanism underlying the 
results of the present study remain to be elucidated, and further spec-
ulation is beyond the scope of this publication. 
The time span during which one might expect changes in estradiol to 
relate to irritability, is unknown. We observed that, in contrast with 
overall variability, week-to-week changes in estradiol were not associ-
ated with concurrent irritability levels. These findings suggest that 
weekly changes in estradiol do not explain changes in irritability during 
that same week. In studies of hormonal links with perimenopausal 
depressive symptoms, others (Gordon et al., 2020) have highlighted the 
importance of accounting for the between-women variability in the di-
rection of the association between estradiol levels and mood, indicating 
that mood in some women may relate to changing levels regardless of 
the direction of the change while the direction of the change (increase 
versus decrease) might have a more important effect on mood for others. 
Hence, analyzing all women together, might "cancel out" a significant 
finding. We observed that a quarter of the women were sensitive to 
estradiol changes, but that the direction of the association between 
weekly estradiol change and irritability varied in direction and strength. 
While this variation in directions of the associations may have "cancelled 
out" an effect, the vast majority of women did not have any association 
of weekly change in estradiol level with irritability, which likely ex-
plains why we did not observe that irritability levels were associated 
with weekly estradiol changes. 
In contrast to estradiol, progesterone levels were not associated with 
irritability. As the perimenopause is characterized by a reduction in 
progesterone peaks due to a reduction in the number of ovulatory cycles 
(O’Connor et al., 2009), our results suggest that sensitivity to variability 
in progesterone is not a risk factor for irritability during the perimeno-
pause. Alternatively, we might not have been able to detect variability 
progesterone as levels were collected weekly, which may have missed an 
ovulatory peak in progesterone during the intervening days. 
Our observation that during the study women reported irritability of 
at least moderate severity at almost half of the visits highlights how 
prevalent irritability is among perimenopausal women who are mildly 
depressed. Though depression severity was the strongest predictor of 
irritability, it explained less than a quarter of the variance of irritability, 
indicating that irritability and depressive symptoms, when measured 
with validated questionnaires, are correlated but commonly represent 
distinct mood states. Irritability is a unique mood symptom in that it is 
not considered a core diagnostic symptom of MDD among adults (AP 
Association, 2013). Moreover, MDD is typically characterized by apathy 
and flattened affect, the reverse of irritability. When women with MDD 
manifest irritability as one of the symptoms of a current depressive 
episode, they have more severe depressive and anxiety symptoms (Perlis 
et al., 2009), and are more likely to have a chronic course (Fava et al., 
2010), and a lower quality of life (Perlis et al., 2005) than those with 
MDD but no irritability. In addition, early reductions in irritability 
predict favorable antidepressant treatment outcomes independently of 
depressive symptom severity (Jha et al., 2019). These observations 
suggest that depressive and irritability symptoms are often comorbid 
and each warrant therapeutic attention to optimize well-being in peri-
menopausal women with affective illness. 
Non-hormonal risk factors for perimenopausal irritability, such as 
VMS and younger age, are consistent with those observed for depression 
severity during the perimenopause (Gordon et al., 2016a, 2016b; 
Bromberger et al., 2001, 2003, 2007, 2010; Avis et al., 1994). However, 
some predictors of depressive symptomatology, such as higher BMI, 
more stressful life events, and a history of MDD (Joffe et al., 2020; 
Bromberger et al., 2007; Gordon et al., 2016a, 2016b), were not pre-
dictive of irritability in our sample. Previous research showed that a 
history of premenstrual syndrome (PMS), rather than of MDD, is asso-
ciated with irritability in women transitioning from pre- to postmeno-
pause (Freeman et al., 2008), Unfortunately, we were unable to examine 
the association with PMS as retrospective reports about PMS were 
missing in half of our study population. However, it is possible that 
perimenopausal irritability may have more in common with a history of 
PMS, which uniquely has irritability as a cardinal symptom, than with 
previous MDD. This supports our observation that perimenopausal ir-
ritability and depression are overlapping dysphoric mood states which 
can be disentangled in both their psychiatric history associations and in 
their concurrent reproductive hormone dynamics. 
Strengths of this study include the weekly, concurrent assessment of 
irritability and depressive symptoms, reproductive hormones, and other 
potential predictors of irritability in a well-characterized cohort of 
perimenopausal women. This is important because concurrent exami-
nation of predictors with the outcome provides more robust insight into 
the real-time risk factors for irritability symptom during this dynamic 
phase of a woman’s life. To the best of our knowledge, this is the first 
study to investigate hormone dynamics rather than absolute levels in 
relation to irritability, a critical advance in our understanding given the 
nature of hormonal fluctuations in the perimenopause. In addition, 
estradiol was assayed using the gold-standard LC/MS, which has 
improved reliability over immunoassays in the low estradiol range 
(Demers, 2008). This study also has some limitations. First, use of 
observational data precludes any causal inference. Second, the weekly 
assessments of predictors and irritability didn’t capture day-to-day 
variability. This may have limited the statistical power to measure 
within-person variability. Future studies should elucidate whether this 
difference in time-span is relevant. Finally, generalizability of results to 
pre- or postmenopausal women without mild-to-moderate depressive 
symptomatology might be limited owing to women’s susceptibility for 
depressive symptomatology during the perimenopause and to the 
unique patterns of variability seen in reproductive hormones during this 
reproductive transition. 
Findings from this study reveal the high prevalence of irritability in 
mildly depressed perimenopausal women. These women were more 
likely to report worse severity of irritability when they had less variable 
estradiol levels, were younger, and had more frequent VMS. Though 
some predictors overlap with those for depression severity, the 
decreased rather than increased variability in estradiol appears to be an 
irritability-specific risk factor. Although our findings need to be repli-
cated, our results indicate that an irritable mood among depressed 
perimenopausal women may be related to neural processes responding 
to a differential estradiol profile. 
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